Updated: Jan 18
Pfizer Inc. announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the entire portfolio of medicines and vaccines for which it has global rights on a not-for-profit basis to enable more excellent health for 1.2 billion people living in 45 lower-income countries.
Launched in May 2022, the Accord, a transformative initiative focused on significantly reducing health inequities that exist between many lower-income countries and the rest of the world, initially included a commitment from Pfizer for access to all its patented medicines and vaccines available in the U.S. or European Union on a not-for-profit basis to 45 lower-income countries.
However, to better align with disease burden and unmet patient needs in these countries, Pfizer will now expand its offering under the Accord to include off-patent products, bringing the total offering from 23 products to around 500 products.
The Accord portfolio now includes patented and off-patent medicines and vaccines that treat or prevent many of the most significant infectious and non-communicable disease threats in lower-income countries.
This includes chemotherapies and oral cancer treatments that potentially treat nearly one million new cancer cases annually in Accord countries. It also has a wide range of antibiotics that can help address the rising morbidity, mortality and costs associated with antimicrobial resistance (AMR) and help prevent around 1.5 million deaths each year in these countries due to bacterial infections in hospitals and community health clinics. As Pfizer launches new medicines and vaccines, those products will also be included in the Accord portfolio on a not-for-profit basis.
“We launched the Accord to help reduce the global health equity gap. We hope to empower country governments and co-create solutions with them and other multi-sector partners to break down many system-level barriers to better health. In the months since the Accord’s launch, we have heard resoundingly from these leaders that access to a broader and more immediate scope of consistent, high-quality products is needed for meaningful and sustainable transformation. We believe this expansion of our product offering, combined with continued efforts to help address the barriers that limit or prevent access, will help us to achieve and even expedite our vision of a world where all people have access to the medicines and vaccines they need to live longer and healthier lives,” said Pfizer Chairman and CEO Albert Bourla.
Since its launch in May 2022, An Accord for a Healthier World continues to progress towards its goals to help address global health equity through medicine, vaccine supply, and health system strengthening.
Rwanda has received nine Pfizer medicines and vaccines for treating certain cancers and infectious and inflammatory diseases. In collaboration with the Rwandan Ministry of Health, Pfizer has provided professional healthcare education and training to support the delivery.
In November, Pfizer deployed its first Global Health Team to the country to help identify opportunities for long-term supply chain optimization. Collaboration is also underway with the Ministries of Health in Malawi, Ghana and Senegal, as well as several other Accord countries, to better understand the critical healthcare needs and opportunities for health system strengthening.
“The Accord is an important step toward sustainable health security for Rwanda and the broader continent. The expanded portfolio offering, combined with public health system strengthening efforts, will further enhance our progress and offer valuable support to key national health initiatives that lead to positive health outcomes,” said His Excellency Paul Kagame, President of Rwanda.
More Great Dubai Route Stories